Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers.

Crosier M, Scott D, Wilson RG, Griffiths CD, May FE, Westley BR.

Clin Cancer Res. 1999 Oct;5(10):2682-8.

2.
3.

Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt.

el-A Helal T, Khalifa A, Kamel AS.

Anticancer Res. 2000 May-Jun;20(3B):2145-50.

PMID:
10928168
4.

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.

5.

Age-associated biomarker profiles of human breast cancer.

Eppenberger-Castori S, Moore DH Jr, Thor AD, Edgerton SM, Kueng W, Eppenberger U, Benz CC.

Int J Biochem Cell Biol. 2002 Nov;34(11):1318-30.

PMID:
12200028
6.

Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.

Khalifeh IM, Albarracin C, Diaz LK, Symmans FW, Edgerton ME, Hwang RF, Sneige N.

Am J Surg Pathol. 2008 Apr;32(4):544-52. doi: 10.1097/PAS.0b013e31815a87e2.

PMID:
18300793
7.

Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.

Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkänen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J.

Clin Cancer Res. 2003 Mar;9(3):923-30.

8.

Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD.

J Natl Cancer Inst. 2010 May 5;102(9):627-37. doi: 10.1093/jnci/djq101. Epub 2010 Apr 28. Erratum in: J Natl Cancer Inst. 2010 Jul 7;102(13):993.

9.

Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow.

Schindlbeck C, Hantschmann P, Zerzer M, Jahns B, Rjosk D, Janni W, Rack B, Sommer H, Friese K.

Int J Gynecol Cancer. 2007 Sep-Oct;17(5):1047-55. Epub 2007 Apr 12.

PMID:
17433065
10.

The role of p53 and Ki67 in Paget's disease of the vulva and the breast.

Ellis PE, Fong LF, Rolfe KJ, Crow JC, Reid WM, Davidson T, MacLean AB, Perrett CW.

Gynecol Oncol. 2002 Aug;86(2):150-6.

PMID:
12144821
11.

[Expression correlation of Ki67 to P53,VEGF,and C-erbB-2 genes in breast cancer and their clinical significances].

Li BJ, Zhu ZH, Wang JY, Hou JH, Zhao JM, Zhang PY, Yao GY, Wang X, Long H, Yang MT, Rong TH.

Ai Zheng. 2004 Oct;23(10):1176-9. Chinese.

PMID:
15473930
12.

[Clinicopathological and biological features of breast cancer in young females and their relationship with prognosis].

Meng J, Lang RG, Fan Y, Fu L.

Zhonghua Zhong Liu Za Zhi. 2007 Apr;29(4):284-8. Chinese.

PMID:
17760256
13.

Biologic characteristics of interval and screen-detected breast cancers.

Gilliland FD, Joste N, Stauber PM, Hunt WC, Rosenberg R, Redlich G, Key CR.

J Natl Cancer Inst. 2000 May 3;92(9):743-9.

PMID:
10793111
14.

Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors.

Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, Di Carlo L, Semeraro A, Daddi G, Darwish S, Stocchi L, Tofanetti FR, Bellezza G, Sidoni A, Tognellini R, Crinò L, Tonato M.

Tumori. 2008 May-Jun;94(3):398-405.

15.

Comparison of the immunohistochemical expression of EGFR, c-erbB2 and p53 protein between primary and recurrent breast cancer.

Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J, Hachitanda Y.

Breast Cancer. 2002;9(2):111-7.

PMID:
12016390
16.

Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer.

Bottini A, Berruti A, Bersiga A, Brizzi MP, Bruzzi P, Aguggini S, Brunelli A, Bolsi G, Allevi G, Generali D, Betri E, Bertoli G, Alquati P, Dogliotti L.

Br J Cancer. 2001 Oct 19;85(8):1106-12.

17.

p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.

Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L.

Clin Cancer Res. 2000 Jul;6(7):2751-8.

18.

HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer.

Arens N, Bleyl U, Hildenbrand R.

Virchows Arch. 2005 May;446(5):489-96. Epub 2005 Apr 19.

PMID:
15838646
19.

17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.

Ariga N, Moriya T, Suzuki T, Kimura M, Ohuchi N, Satomi S, Sasano H.

Anticancer Res. 2000 Mar-Apr;20(2B):1101-8.

PMID:
10810403
20.

Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.

Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, Iwase H.

Breast Cancer Res. 2004;6(1):R24-30. Epub 2003 Nov 7.

Supplemental Content

Support Center